CBD-Derived Drug Manufacturer Tetra Bio-Pharma Announced a Strategic Partnership with Avicanna
The Dank Investor Posted On February 16, 2022 
Tetra Bio-Pharma Inc. (TSX:TBP) (OTCQB:TBPMF), a leading company in cannabinoid-derived therapeutic research, announced today that it’s entered into a non-binding agreement with Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN).
Avicanna registers and distributes Tetra’s prescription products in Latin America and South America. This will allow Tetra to begin sales earlier than expected.
Tetra Bio-Pharma‘s pharmaceutical pipeline relies on Avicanna’s Active Pharmaceutical Ingredients (APIs). Avicanna’s low-cost and sustainable businesses in Colombia would supply the phyto-cannabinoid APIs.
About Avicanna Inc.
The Avicanna Corporation is a global biopharmaceutical company focused on the development, commercialization, and advancement of medical and pharmaceutical products derived from cannabinoids for global consumers.
Avicanna performs most of its research in Canada at the Johnson & Johnson Innovation Centre, JLABS @ Toronto, in the MaRS Discovery District, leading global cannabinoid breakthroughs.
The company works closely with Canada’s most prestigious academic and medical institutions. Avicanna has built an industry-leading scientific platform, including advanced R&D and clinical development, that has resulted in the commercialization of over twenty products in four market segments: Cannabis Raw Materials and feminized Seeds, Pharmaceutical Pipeline, Medical Cannabis & Wellness Products, and CBD Derma Cosmetic Products.
Avicanna’s pharmaceutical pipeline supports and co-development for clinical development and registration at Health Canada and FDA levels.
About Tetra Bio-Pharma
Tetra Bio-Pharma is a pioneer in cannabinoid-derived medication discovery and development, with an FDA and Health Canada-approved clinical program targeted at bringing novel prescription pharmaceuticals and treatments to patients and healthcare providers.
They’ve developed a pipeline of cannabinoid-based medicinal solutions for various medical diseases, including pain, inflammation, and oncology, thanks to their evidence-based scientific approach.
Tetra Bio-Pharma focuses on providing rigorous scientific validation and safety data required for inclusion into the existing biopharma business by regulators, clinicians, and insurance companies, with patients at the center of what they do.
About the Strategic Partnership
Tetra’s Chief Commercial Officer, Steeve Neron, noted, “Tetra will require many dependable API providers, such as Avicanna, to support QIXLEEF activities, including marketing authorization and global sales and distribution.
Tetra’s proprietary investigational novel medication, QIXLEEFTM, is now being evaluated in two FDA-approved clinical trials in the United States. Avicanna’s established distributions channels in Latin and South America may further aid Tetra’s product commercialization in certain jurisdictions “.
Avicanna’s Chief Executive Officer, Aras Azadian, also discussed the possibility. “We are excited to work with the Tetra team, which has been at the forefront of cannabinoid-prescription goods in many areas.
The global pharmaceutical business is maturing and moving towards evidence-based medicine, which enables both companies to leverage their leadership positions to generate lucrative commercial outcomes.”
